

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## HEALTH TECHNOLOGY APPRAISAL PROGRAMME

### Equality impact assessment – Guidance development

#### STA Secukinumab for treating moderate to severe hidradenitis suppurativa

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

#### Consultation

- |   |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
|---|

The following issues were identified during scoping:
--

- |  |
|--|
| <ul style="list-style-type: none"><li>• Incidence of hidradenitis suppurative is higher in people of African-Caribbean family background, as compared with people of European family background</li><li>• Peak prevalence is in females of child-bearing age</li></ul> |
|--|

These issues are discussed in section 3.20 of the draft guidance.
---

- |  |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
|--|

No additional issues raised.
------------------------------

- |  |
|--|
| 3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these? |
|--|

No additional issues raised.
------------------------------

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?
No

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?
No

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?
N/A

7. Have the committee's considerations of equality issues been described in the draft guidance, and, if so, where?
Section 3.20 of draft guidance.

**Approved by Associate Director (name):** .....Richard Diaz.....

**Date:** 19 June 2023

## Final draft guidance

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these?

No

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

No

5. Have the committee's considerations of equality issues been described in the final draft guidance, and, if so, where?

See final draft guidance, section 3.20.

**Approved by Associate Director (name):** ...Richard Diaz.....

**Date:** 17 Oct 2023